Font

Aa Aa Aa

Background color

A A

Site version

Color Black and white
Drugs

Vinpocetinе-Darnitsa

Psychostimulants and nootropic agents

The active substance, vinpocetine, improves brain metabolism and blood supply as well as the rheological properties of blood. The drug has neuroprotective effects—it attenuates the harmful effects of cytotoxic reactions caused by stimulant amino acids.

Neurology: various forms of cerebrovascular pathology (conditions after impaired cerebral circulation (stroke), vertebrobasilar insufficiency, vascular dementia, cerebral atherosclerosis, posttraumatic and hypertensive encephalopathy). The drug promotes a decrease in the mental and neurological symptoms in cerebrovascular pathology.

Ophthalmology: chronic vascular diseases of the choroid and retina (e.g., thrombosis, central retinal artery, or vein obstruction).

Otorhinolaryngology: age-related hearing loss due to acute vascular pathology, hearing impairment of toxic (drug-related) or other nature (idiopathic, caused by noise), Ménière's disease, tinnitus.

The drug should only be administered by slow intravenous drip (with the rate not exceeding 80 drops per minute).

The drug is contraindicated for subcutaneous, intramuscular administration, and as concentrated solution for intravenous injection.

The drug can be diluted by saline or glucose-containing solutions for infusion.

Solution for infusion should be used within 3 hours after preparation.

The initial daily dose of the drug is usually 20 mg diluted in 500 mL of solution for infusion. If necessary, the dose can be increased up to 1 mg/kg of body weight per day for 2–3 days, depending on the drug tolerability.

The initial daily dose of the drug is usually 50 mg diluted in 500 mL of solution for infusion calculated for a body weight of 70 kg.

The average course of treatment is 10 to 14 days.

After finishing the infusion therapy, it is recommended to continue the treatment with the drug in tablet form.

Specialized edition for medical institutions and doctors.